|
시장보고서
상품코드
2091701
섬유낭성 유방 질환 시장 규모, 점유율 및 성장 분석 : 질환 유형별, 치료법별, 진단 방법별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Fibrocystic Breast Condition Market Size, Share, and Growth Analysis, By Condition Type, By Treatment Type, By Diagnosis Type, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 섬유낭성 유방 질환 시장 규모는 2024년에 66억 7,000만 달러로 평가되며, 2025년 70억 6,000만 달러에서 2033년까지 110억 7,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 5.8%로 성장할 것으로 전망되고 있습니다.
세계의 섬유낭성 유방 질환 시장은 유방 결절 증후군을 치료하기 위한 진단 툴, 의약품 치료 및 서비스에 대한 수요가 증가함에 따라 확대되고 있습니다. 이 흔한 질환은 폐경 전 여성의 상당수에게 영향을 미치고 있으며, 공중보건 구상과 언론을 통한 인식 제고 활동으로 인해 건강 증진을 위한 행동이 촉진되고 있습니다. 초음파 검사나 유방촬영술 등의 진단법이 고도화되는 것은 물론, 기존의 진통 요법에서 선택적 에스트로겐 수용체 조절제(SERM)나 뉴트라슈티컬스 등 다양한 치료법으로의 전환이 두드러지는 추세입니다. 또한 유전체 프로파일링과 표적 치료의 통합을 통해 치료의 정확도가 향상되고 재발률이 감소하고 있습니다. 이러한 진화는 동반 진단제에 대한 수요를 촉진하고, 생명공학 혁신의 길을 열어주며, 궁극적으로는 시장내 효과적인 치료 파이프라인에 대한 투자를 지원하고 있습니다.
세계 섬유낭성 유방 질환 시장의 성장 요인
전 세계 섬유낭성 유방 질환 시장은 환자와 의료 종사자들 사이에서 인지도가 높아짐에 따라 크게 성장하고 있습니다. 계몽 프로그램, 온라인 자료, 지역사회의 활동이 확대됨에 따라 이 질환에 대한 지식이 널리 퍼지고 있으며, 조기 진단과 관리에 도움이 되는 환경이 조성되고 있습니다. 이러한 이해의 심화를 통해 더 많은 환자가 진단 서비스를 받고 치료 계획을 따르게 되었으며, 그 결과 치료제의 잠재 시장이 확대되고 있습니다. 또한 이 질환에 대한 사회적 논의가 활발해짐에 따라 편견을 해소하는 데 기여하고, 의료 종사자들이 교육을 우선시하도록 유도함으로써 시장 성장을 더욱 촉진하고 있습니다. 지원 단체와 제약 회사의 협력 체제는 인식 제고 활동을 한층 더 강화하고, 전문적인 치료 옵션에 대한 관심을 지속시키고 있습니다.
세계 섬유낭성 유방 질환 시장의 제약 요인
전 세계 섬유낭성 유방 질환 시장은 전문 유방 클리닉이나 훈련을 받은 의료 종사자에 대한 접근을 제한하는 지역적·사회경제적 격차로 인해 큰 과제에 직면해 있습니다. 의료 서비스가 충분히 제공되지 않는 지역에 거주하는 많은 환자들은 장거리 이동, 긴 대기 시간, 포괄적이고 다직종 협력을 통한 치료 옵션에 대한 접근 제한과 같은 장벽에 직면해 있습니다. 이러한 장벽들은 진단 지연을 초래하고, 환자가 권장되는 관리 계획을 준수하는 데 방해가 될 수 있습니다. 그 결과, 해당 지역에서는 시장 침투가 제한적이며, 치료 및 진단 솔루션을 제공하는 업체 모두의 성장 가능성이 저해되고 있습니다. 지역 차원의 노력을 통해 인식 제고 활동과 돌봄 서비스의 질 향상에 힘쓰고 있지만, 이러한 노력을 확대하기 위해서는 막대한 자원이 필요합니다.
세계 섬유낭성 유방 질환 시장의 동향
전 세계 섬유낭성 유방 질환 시장에서는 바이오마커 연구의 발전과 호르몬 요법의 개인화를 배경으로, 개인 맞춤형 치료 방식으로의 뚜렷한 전환이 나타나고 있습니다. 임상의들은 환자별 내분비 프로파일, 증상의 중증도, 생활습관 요인을 바탕으로 치료 계획을 개별적으로 조정하는 데 점점 더 주력하고 있으며, 그 결과 환자의 치료 순응도 향상과 치료 성과 개선으로 이어지고 있습니다. 각 제약사는 이러한 동향에 대응하여, 섬유낭성 유방 질환을 위해 특별히 설계된 선택적 조절제를 개발하고 있습니다. 이러한 변화하는 상황은 더 나은 증상 관리를 촉진하고, 의료 제공자와 환자 간의 공동 의사결정을 이끌어내며, 궁극적으로 맞춤형 호르몬 관리를 시장의 주요 성장 동력으로 자리매김하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 섬유낭성 유방 질환 시장 규모 : 컨디션 유형별
세계의 섬유낭성 유방 질환 시장 규모 : 치료 유형별
세계의 섬유낭성 유방 질환 시장 규모 : 진단 유형별
세계의 섬유낭성 유방 질환 시장 규모 : 최종사용자별
세계의 섬유낭성 유방 질환 시장 규모 : 유통 채널별
세계의 섬유낭성 유방 질환 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.07.22Global Fibrocystic Breast Condition Market size was valued at USD 6.67 Billion in 2024 and is poised to grow from USD 7.06 Billion in 2025 to USD 11.07 Billion by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).
The global market for fibrocystic breast condition is expanding due to rising demand for diagnostic tools, pharmaceutical treatments, and services addressing breast lump syndrome. This widespread condition affects a significant portion of premenopausal women, prompting health-seeking behaviors fueled by increased awareness from public health initiatives and media. Enhanced diagnostic methods, including ultrasound and mammography, alongside a shift from traditional pain relief to a diverse range of treatments-such as selective estrogen receptor modulators and nutraceuticals-are notable trends. Moreover, the integration of genomic profiling with targeted therapies is enhancing treatment accuracy and reducing recurrence rates. This evolution is fostering demand for companion diagnostics and opening avenues for biotech innovation, ultimately driving investment in effective treatment pipelines within the market.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Fibrocystic Breast Condition market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Fibrocystic Breast Condition Market Segments Analysis
Global fibrocystic breast condition market is segmented by condition type, treatment type, diagnosis type, end user, distribution channel and region. Based on condition type, the market is segmented into Non-Proliferative Fibrocystic Breast Changes, Proliferative Fibrocystic Breast Changes Without Atypia and Proliferative Fibrocystic Breast Changes With Atypia. Based on treatment type, the market is segmented into Supportive & Symptomatic Management, Pharmacological Therapy, Hormonal Therapy, Surgical Intervention and Others. Based on diagnosis type, the market is segmented into Clinical Breast Examination, Mammography, Breast Ultrasound, Magnetic Resonance Imaging (MRI) and Fine-Needle Aspiration (FNA) & Biopsy. Based on end user, the market is segmented into Hospitals, Breast Care Clinics, Diagnostic Imaging Centers and Ambulatory Care Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Fibrocystic Breast Condition Market
The global market for Fibrocystic Breast Condition is being significantly driven by an increase in awareness among patients and healthcare providers. As outreach programs, online resources, and community initiatives proliferate, individuals are becoming more knowledgeable about the condition, fostering an environment conducive to early diagnosis and management. This growth in understanding encourages more patients to pursue diagnostic services and follow treatment plans, thereby expanding the potential market for therapeutic products. Additionally, heightened public conversations about the condition help eliminate stigma and lead healthcare professionals to prioritize education, which further fuels market growth. Collaborative efforts between advocacy organizations and pharmaceutical companies further enhance outreach and maintain interest in specialized treatment options.
Restraints in the Global Fibrocystic Breast Condition Market
The Global Fibrocystic Breast Condition market faces significant challenges due to geographic and socioeconomic disparities that restrict access to specialized breast clinics and trained healthcare professionals. Many patients living in underserved regions encounter obstacles such as long travel distances, extended wait times, and limited access to comprehensive, multidisciplinary treatment options. These barriers can result in delayed diagnoses and hinder patients' adherence to recommended management plans. As a consequence, market penetration is limited in these areas, stifling growth potential for providers of both therapeutic and diagnostic solutions. While local initiatives strive to enhance outreach and care, expanding these efforts requires substantial resources.
Market Trends of the Global Fibrocystic Breast Condition Market
The Global Fibrocystic Breast Condition market is witnessing a notable shift towards personalized treatment approaches, driven by advancements in biomarker research and individualization of hormonal therapy. Clinicians are increasingly focusing on tailoring treatment regimens based on unique endocrine profiles, symptom severity, and lifestyle factors, leading to enhanced patient adherence and improved outcomes. Pharmaceutical companies are responding to this trend by developing selective modulators specifically designed for fibrocystic breast conditions. This evolving landscape fosters better symptom management, involves collaborative decision-making between healthcare providers and patients, and ultimately positions personalized hormonal management as a pivotal growth driver in the market.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Fibrocystic Breast Condition Market Size by Condition Type & CAGR (2026-2033)
- Market Overview
- Non-Proliferative Fibrocystic Breast Changes
- Proliferative Fibrocystic Breast Changes Without Atypia
- Proliferative Fibrocystic Breast Changes With Atypia
Global Fibrocystic Breast Condition Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Supportive & Symptomatic Management
- Pharmacological Therapy
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Hormonal Agents
- Analgesics
- Dietary & Nutritional Supplements
- Others
- Hormonal Therapy
- Surgical Intervention
- Others
Global Fibrocystic Breast Condition Market Size by Diagnosis Type & CAGR (2026-2033)
- Market Overview
- Clinical Breast Examination
- Mammography
- Breast Ultrasound
- Magnetic Resonance Imaging (MRI)
- Fine-Needle Aspiration (FNA) & Biopsy
Global Fibrocystic Breast Condition Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Breast Care Clinics
- Diagnostic Imaging Centers
- Ambulatory Care Centers
Global Fibrocystic Breast Condition Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Fibrocystic Breast Condition Market Size & CAGR (2026-2033)
- North America (Condition Type, Treatment Type, Diagnosis Type, End User, Distribution Channel)
- US
- Canada
- Europe (Condition Type, Treatment Type, Diagnosis Type, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Condition Type, Treatment Type, Diagnosis Type, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Condition Type, Treatment Type, Diagnosis Type, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Condition Type, Treatment Type, Diagnosis Type, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GE HealthCare Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hologic, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Koninklijke Philips N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Canon Medical Systems Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- FUJIFILM Holdings Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Becton, Dickinson and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Argon Medical Devices, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
